Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

We report the first 5-year follow-up of any first-line phase III immunotherapy trial for non–small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials.gov identifier: NCT02142738) is an open-label, randomized controlled trial of pembrolizumab compared with platinum-based chemotherapy in patients w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Oncol
Hauptverfasser: Reck, Martin, Rodríguez-Abreu, Delvys, Robinson, Andrew G., Hui, Rina, Csőszi, Tibor, Fülöp, Andrea, Gottfried, Maya, Peled, Nir, Tafreshi, Ali, Cuffe, Sinead, O'Brien, Mary, Rao, Suman, Hotta, Katsuyuki, Leal, Ticiana A., Riess, Jonathan W., Jensen, Erin, Zhao, Bin, Pietanza, M. Catherine, Brahmer, Julie R.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Wolters Kluwer Health 2021
Schlagworte:
RAPID COMMUNICATIONS
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8280089/
https://ncbi.nlm.nih.gov/pubmed/33872070
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.21.00174
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge